The Mechanism of MicroRNAs Network in Alzheimer's Disease

Shanghai Mental Health Center

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05055310

Acronym

MicroRNAs AD

Enrollment

1000

Registered

2021-09-24

Start date

2016-10-31

Completion date

2019-12-31

Last updated

2021-09-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease

Keywords

MicroRNAs, Alzheimer's Disease, Validation

Brief summary

MicroRNAs network, such as MicRNA107 et al, regulate the pathology of Alzheimer's disease and the clinical validation in diagnosis AD.

Interventions

DIAGNOSTIC_TESTMicRNAs test

plasma micRNAs concentration

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

60 Years to 90 Years

Healthy volunteers

Yes

Inclusion criteria

* NIA-AA MCI due to AD clinical criteria for MCI due to AD * NIA-AA AD clinical criteria for AD

Exclusion criteria

* Other type of dementia

Design outcomes

Primary

Measure	Time frame	Description
MicRNAs diagnosis validation for aMCI	5 years	MicRNAs concentration in plasma among three groups

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026